|
|
 |
|
Viewing report
|
|
|
|
Emerging Cancer Therapeutics
Bioseeker, Jan 2002, Pages: 256
This new report is designed to provide you with in-depth coverage, candid information and analysis of the tumor antigen field. This report presents an up-to-date “de novo” approach and is a significant tool for strategic planning in tumor antigen commercialization whether being a CEO, business developer at a biotech enterprise or an investment analyst at a VC firm. We have identified more than 60 tumor antigens that are in line for commercialization. At least 40 companies are working actively in this field with more than 3,000 people employed and an estimated expenditure of 1.8 billion USD year 2000.
In this report, we present an extensive overview of business to business (b2b) collaborations in the competitive landscape of tumor antigen commercialization. Out of 40 companies, 35 have b2b collaborations. At least eleven of these form interesting clusters. Thirteen of the companies analysed have no big pharma collaboration. There have been five acquisitions, one formation and breakage of joint venture, and eleven broad corporate partnership formations.
We not only provide you with an extensive information platform (see our Basic platform reports) but also include extensive company profiles with short description of the company, technology platforms, financial data, collaborations and product pipelines. Achievement benchmarking in R&D, company pipelines, alliances and financial situations and clinical trial progress are described. We also present in depth analysis and evaluation of different discovery and delivery technology platforms. The report includes an extensive chapter for future projections, where BioSeeker Group subjectively discusses and assesses possible outcomes for these companies.
This report “Commercializing On Tumor Antigens: Analytical Perspectives” analyzes the activities among companies working mainly on antigen, cellular and genetic vaccines for cancer therapy and provides the strategic analysis needed to sharpen your competitive edge. We focus on achievements and pitfalls that have been experienced by companies trying to commercialize on these techniques.
Customers who bought this item also bought
Cancer - Emerging Cancer Therapeutics
Phosphatases: Emerging Role in Signal Transduction, Human Therapeutics, & As Drug Targets
Breast Cancer Therapeutics: How Innovation Is Shaping Future Therapies
Cancer Therapeutics 2006: Market Dynamics and R&D Trends
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
Emerging Antiviral Drug Targets
Progress in RNA-Based Therapeutics
New Concepts in Cancer Therapeutics
|
|
|
|
